EU signs joint procurement contract for remdesivir supply
- Life
- Reuters
- Published Date: 10:42 | 08 October 2020
- Modified Date: 10:42 | 08 October 2020
The European Commission said on Thursday it had signed a contract with U.S. drugmaker Gilead for the supply of up to 500,000 treatment courses for remdesivir, sharply increasing the supply of the COVID-19 treatment in Europe.
The Commission, which has overseen joint purchases of vaccines in the European Union, said there were 36 signatories to the agreement, including all EU countries, six Balkan candidate and potential EU members, Britain and the other European Economic Area countries Iceland, Liechtenstein and Norway.
- Russia registers nearly 11,500 new virus cases
- American poet Louise Gluck wins Nobel Literature Prize
- Austria's daily coronavirus cases break record set in March, paper says
- Top German health official says 'uncontrolled' COVID-19 spread, 10,000 cases a day possible
- France braces for wider COVID-19 restrictions